#United States #Robbins Geller #San Diego #Class Action #Zoetis Inc.

Opportunity for Zoetis Investors

Robbins Geller Rudman & Dowd LLP, a leading law firm specializing in shareholder rights, has announced a critical opportunity for investors in Zoetis Inc. (NYSE: ZTS) who have experienced substantial losses. If you purchased or acquired securities of Zoetis between January 14, 2025, and May 6, 2026, you could qualify to lead a class action lawsuit against the company. The deadline to apply for lead plaintiff status is July 27, 2026.

Lawsuit Details

The class action lawsuit, officially known as City of Ann Arbor Retiree Health Care Benefit Plan Trust v. Zoetis Inc., is filed under case number 26-cv-04401 in the Southern District of New York. The allegations against Zoetis focus on violations of the Securities Exchange Act of 1934. It is claimed that the company and its executives made misleading statements regarding the performance of its key products and failed to disclose critical information that affected their market positions.

Allegations of Misleading Statements

According to the lawsuit, Zoetis’ growth in veterinarian prescriptions and sales for its premier veterinary care products, including Librela, Apoquel, Cytopoint, and Simparica Trio, has been deteriorating. Notably, the following key points have been mentioned in the suit:
1. Declining Adoption of Librela: The usage of Librela, a canine pain management solution, has dropped significantly following FDA warnings about neurological risks linked to its use.
2. Market Share Losses for Simparica Trio: The performance of Simparica Trio, another flagship product, has been impacted by lower-priced alternatives, further intensifying competition amidst a slowing market.
3. Increasing Pressure on Dermatology Products: Amidst rising competitors, the dermatological medications Apoquel and Cytopoint were reportedly facing declining market shares.

Financial Impacts and Stock Price Drops

Throughout the class period, Zoetis released several quarters' financial results indicating weakening sales trends, particularly with its companion animal products:

• - On August 5, 2025, Zoetis announced disappointing second-quarter financial results, causing the stock to plummet nearly 4%.
• - The third quarter results released on November 4, 2025, disclosed ongoing challenges in Librela sales and competitive pressures, resulting in a 14% drop in stock price.
• - By February 12, 2026, the fourth-quarter results revealed continued slumping growth and heightened competition, contributing to another decline in stock value.
• - Finally, the report of first-quarter 2026 results on May 7 showed declining sales and increased competition across key medications, leading to a more than 21% drop in stock price.

Becoming a Lead Plaintiff

Qualified investors are encouraged to take action before the upcoming deadline. The Private Securities Litigation Reform Act of 1995 allows any investor who owned Zoetis securities within the stated time frame to apply as a lead plaintiff in the class action. The lead plaintiff will represent all affected individuals and can appoint a law firm of their choice for litigation. Importantly, participation as a lead plaintiff does not restrict other investors' potential recovery.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is recognized as one of the most successful law firms globally in securities fraud and shareholder litigation, boasting a strong track record of recovering over $8.4 billion for investors in the last five years alone. With its extensive resources and commitment to shareholder rights, Robbins Geller stands ready to assist Zoetis investors seeking justice and compensation for their losses. For more information about the class action lawsuit, investors may visit the Robbins Geller website.

In conclusion, Zoetis Inc. investors are urged to evaluate their options and consider participating in the upcoming class action lawsuit to ensure their rights are protected as the case unfolds. Take necessary steps today and reach out to Robbins Geller for assistance on how to move forward.